Cargando…

The Efficacy of Ginsenoside Rg3 Combined with First-line Chemotherapy in the Treatment of Advanced Non-Small Cell Lung Cancer in China: A Systematic Review and Meta-Analysis of Randomized Clinical Trials

Background: For advanced non-small cell lung cancer (NSCLC) patients, first-line chemotherapy is the main treatment in the clinic despite its efficacy is limited and adverse effects are always inescapable. Ginsenoside Rg3, an anti-cancer active ingredient by suppressing angiogenesis, has been increa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Peng, Ze, Wu, Wen Wen, Yi, Ping
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8012535/ https://www.ncbi.nlm.nih.gov/pubmed/33815097 http://dx.doi.org/10.3389/fphar.2020.630825

Ejemplares similares

Ginsenoside Rg3 for Chemotherapy-Induced Myelosuppression: A Meta-Analysis and Systematic Review
por: Pan, Linlin, et al.
Publicado: (2020)

Relationship Between Ginsenoside Rg3 and Metabolic Syndrome
por: Lee, Hyunji, et al.
Publicado: (2020)

Ginsenoside Rg1 as an Effective Regulator of Mesenchymal Stem Cells
por: He, Fang, et al.
Publicado: (2020)

Ginsenoside Rg5 Inhibits Succinate-Associated Lipolysis in Adipose Tissue and Prevents Muscle Insulin Resistance
por: Xiao, Na, et al.
Publicado: (2017)

Anti-adipogenic Effects and Mechanisms of Ginsenoside Rg3 in Pre-adipocytes and Obese Mice
por: Zhang, Longyun, et al.
Publicado: (2017)

Antioxidant and anti-inflammatory properties of ginsenoside Rg1 for hyperglycemia in type 2 diabetes mellitus: systematic reviews and meta-analyses of animal studies
por: Xie, Qian, et al.
Publicado: (2023)

Ginsenoside Rg1 Ameliorates Neuroinflammation via Suppression of Connexin43 Ubiquitination to Attenuate Depression
por: Wang, Huiqin, et al.
Publicado: (2021)

Cost-Effectiveness of Domestic PD-1 Inhibitor Camrelizumab Combined With Chemotherapy in the First-Line Treatment of Advanced Nonsquamous Non–Small-Cell Lung Cancer in China
por: Qiao, Liu, et al.
Publicado: (2021)

Pharmacological properties, molecular mechanisms and therapeutic potential of ginsenoside Rg3 as an antioxidant and anti-inflammatory agent
por: Wang, Jing, et al.
Publicado: (2022)

Combination of Ginsenosides Rb2 and Rg3 Promotes Angiogenic Phenotype of Human Endothelial Cells via PI3K/Akt and MAPK/ERK Pathways
por: Choi, Ran Joo, et al.
Publicado: (2021)

Ginsenoside Rg3 (Shenyi Capsule) Combined with Chemotherapy for Digestive System Cancer in China: A Meta-Analysis and Systematic Review
por: Pan, Linlin, et al.
Publicado: (2019)

Protective effects of ginsenosides Rg1 and Rb1 against cognitive impairment induced by simulated microgravity in rats
por: Jiang, Ning, et al.
Publicado: (2023)

Cost-effectiveness analysis of PD-1 inhibitors combined with chemotherapy as first-line therapy for advanced esophageal squamous-cell carcinoma in China
por: Liu, Shixian, et al.
Publicado: (2023)

Cost-Effectiveness Analysis of Sintilimab Combined with Chemotherapy Versus Chemotherapy Alone as the First-Line Treatment for Advanced Esophageal Cancer
por: Ye, Zhuo-Miao, et al.
Publicado: (2022)

Ginsenoside Rg3 Mitigates Atherosclerosis Progression in Diabetic apoE–/– Mice by Skewing Macrophages to the M2 Phenotype
por: Guo, Mengqi, et al.
Publicado: (2018)

Ginsenoside Rg1 interferes with the progression of diabetic osteoporosis by promoting type H angiogenesis modulating vasculogenic and osteogenic coupling
por: Chen, Wenhui, et al.
Publicado: (2022)

Antiarrhythmic effects of ginsenoside Rg2 on calcium chloride–induced arrhythmias without oral toxicity
por: Gou, Dongxia, et al.
Publicado: (2020)

Quantitative comparison of the efficacies and safety profiles of three first-line non-platinum chemotherapy regimens for advanced non-small cell lung cancer
por: Yang, Qian-Yu, et al.
Publicado: (2022)

A systematic review and meta-analysis of Ginsenoside-Rg1 (G-Rg1) in experimental ischemic stroke
por: Xie, Cheng-long, et al.
Publicado: (2015)

The cost-effectiveness of cemiplimab plus chemotherapy as the first-line treatment for advanced non-small cell lung cancer
por: Lu, Tingting, et al.
Publicado: (2023)

Effects of ginsenoside Rg3 on epigenetic modification in ovarian cancer cells
por: Zhao, Lingqin, et al.
Publicado: (2019)

Ginsenoside Rg1 can reverse fatigue behavior in CFS rats by regulating EGFR and affecting Taurine and Mannose 6-phosphate metabolism
por: Lei, Chaofang, et al.
Publicado: (2023)

Ginsenoside Rg3 Alleviates ox-LDL Induced Endothelial Dysfunction and Prevents Atherosclerosis in ApoE(−/−) Mice by Regulating PPARγ/FAK Signaling Pathway
por: Geng, Jianan, et al.
Publicado: (2020)

Ginsenoside Rg5 overcomes chemotherapeutic multidrug resistance mediated by ABCB1 transporter: in vitro and in vivo study
por: Feng, Sen-Ling, et al.
Publicado: (2020)

Comparison of the Protective Effects of Ginsenosides Rb1 and Rg1 on Improving Cognitive Deficits in SAMP8 Mice Based on Anti-Neuroinflammation Mechanism
por: Yang, Yujie, et al.
Publicado: (2020)

Cost-Effectiveness of Bevacizumab Biosimilar LY01008 Combined With Chemotherapy as First-Line Treatment for Chinese Patients With Advanced or Recurrent Nonsquamous Non-Small Cell Lung Cancer
por: Luo, Xia, et al.
Publicado: (2022)

Proteomic analyses reveal that ginsenoside Rg3(S) partially reverses cellular senescence in human dermal fibroblasts by inducing peroxiredoxin
por: Jang, Ik-Soon, et al.
Publicado: (2020)

Analyses of mRNA Profiling through RNA Sequencing on a SAMP8 Mouse Model in Response to Ginsenoside Rg1 and Rb1 Treatment
por: Zhang, Shuai, et al.
Publicado: (2017)

Ginsenoside Rg1-Notoginsenoside R1-Protocatechuic Aldehyde Reduces Atherosclerosis and Attenuates Low-Shear Stress-Induced Vascular Endothelial Cell Dysfunction
por: Zhang, Lei, et al.
Publicado: (2021)

Efficacy and Safety of Different Doses of Bevacizumab Combined With Pemetrexed and Platinum in First-Line Treatment of Advanced NSCLC: A Retrospective-Real World Study
por: Zhou, Chun-Hua, et al.
Publicado: (2021)

Cost-Effectiveness of Pembrolizumab Plus Chemotherapy as First-Line Therapy for Advanced Oesophageal Cancer
por: Wu, Meiyu, et al.
Publicado: (2022)

Anti-Angiogenic Properties of Ginsenoside Rg3
por: Nakhjavani, Maryam, et al.
Publicado: (2020)

Pharmacological activities of ginsenoside Rg5 (Review)
por: Liu, Ming-Yang, et al.
Publicado: (2021)

Comparative Pharmacokinetics of Ginsenoside Rg(3) and Ginsenoside Rh(2) after Oral Administration of Ginsenoside Rg(3) in Normal and Walker 256 Tumor-bearing Rats
por: Fan, He, et al.
Publicado: (2016)

Tislelizumab plus chemotherapy versus pembrolizumab plus chemotherapy for the first-line treatment of advanced non-small cell lung cancer: systematic review and indirect comparison of randomized trials
por: Guo, Yimeng, et al.
Publicado: (2023)

First-line sintilimab plus chemotherapy in locally advanced or metastatic esophageal squamous cell carcinoma: A cost-effectiveness analysis from China
por: Shen, Jian, et al.
Publicado: (2022)

Ginsenoside Rg3 Attenuates Lipopolysaccharide-Induced Acute Lung Injury via MerTK-Dependent Activation of the PI3K/AKT/mTOR Pathway
por: Yang, Jing, et al.
Publicado: (2018)

Amino acid modified OCMC-g-Suc-β-CD nanohydrogels carrying lapatinib and ginsenoside Rg1 exhibit high anticancer activity in a zebrafish model
por: Cui, Li, et al.
Publicado: (2023)

The Safety Evaluation of Salvianolic Acid B and Ginsenoside Rg1 Combination on Mice
por: Zhao, Qun, et al.
Publicado: (2015)

Molecular signaling of ginsenosides Rb1, Rg1, and Rg3 and their mode of actions
por: Mohanan, Padmanaban, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_n11br3nsu2l8vthkcsj6iu4stk